RT Journal Article
SR Electronic
T1 Evaluating the World Health Organization’s HEARTS Model for Hypertension and Diabetes Management: A Pilot Implementation Study in Guatemala
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.07.24315061
DO 10.1101/2024.10.07.24315061
A1 Wellmann, Irmgardt Alicia
A1 Ayala, Luis Fernando
A1 Valley, Taryn M.
A1 Irazola, Vilma
A1 Huffman, Mark D.
A1 Heisler, Michele
A1 Rohloff, Peter
A1 Donis, Rocío
A1 Palacios, Eduardo
A1 Ramírez-Zea, Manuel
A1 Flood, David
YR 2024
UL http://medrxiv.org/content/early/2024/10/08/2024.10.07.24315061.abstract
AB Background The World Health Organization HEARTS Technical Package is a widely implemented global initiative to improve the primary care management of cardiovascular disease risk factors. The study’s objective is to report outcomes from a pilot implementation trial of integrated hypertension and diabetes management based on the HEARTS model in Guatemala.Methods We conducted a single-arm pilot implementation trial over 6 months from October 2023 to May 2024 in 11 Guatemalan Ministry of Health primary care facilities in two districts. The pilot evaluated a package of five HEARTS-aligned implementation strategies to improve the pharmacological treatment of hypertension and diabetes. The primary outcomes were feasibility and acceptability, measured through 20 structured interviews with Ministry of Health employees and by examining enrollment and retention. Secondary outcomes included a suite of implementation and clinical outcomes, including treatment rate.Results The study enrolled 964 patients, of whom 58.8% had hypertension only, 30.4% had diabetes only, and 10.8% had both conditions. Surveys on feasibility and acceptability among Ministry of Health staff had a median score of 5.0 (IQR: 5.0 to 5.0) and 5.0 (IQR range: 4.8 to 5.0), respectively, exceeding the prespecified benchmark of ≥3.5. Both districts achieved the prespecified benchmark of enrolling ≥25 hypertension patients and ≥25 diabetes patients. Only 36% of patients attended a follow-up visit within three months, lower than the prespecified benchmark of ≥75%. M treatment rates during the pilot increased by 22.3 (95% CI: 16.2 to 28.4; P<0.001) and 3.5 (95% CI: -1.6 to 8.7; P=0.17) patients per month for hypertension and diabetes, respectively.Conclusions Implementation of an integrated hypertension and diabetes model based on HEARTS was generally feasible and acceptable in the Ministry of Health in Guatemala. Findings can refine national scale-up in Guatemala and inform HEARTS implementation projects in other settings.Competing Interest StatementDF and IAW have received consultant fees from the World Health Organization. IAW and LFA have received consultant fees from the Pan American Health Organization. MDH has pending patents for heart failure polypills, has received travel support from the World Heart Federation and has consulted for PwC Switzerland. George Health Enterprises Pty Ltd (GH) and its subsidiary, George Medicines Pty Ltd, have received investment funds to develop fixed-dose combination products, including combinations of blood pressure-lowering drugs. GH is the social enterprise arm of The George Institute for Global Health.Clinical TrialClinicalTrials.gov: NCT06080451Clinical Protocols https://implementationsciencecomms.biomedcentral.com/articles/10.1186/s43058-023-00539-8 Funding StatementFunding support for this study is provided by the National Heart, Lung, And Blood Institute of the National Institutes of Health (K23HL161271) and the University of Michigan Caswell Diabetes Institute. TMV was funded in part by the NIH Medical Scientist Training Program grant T32GM140935. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the ethics committees of the Ministry of Health of Guatemala (07-2023), the Institute of Nutrition of Central America and Panama (CIE-REV 124/2023), and the University of Michigan (HUM00234613).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDeidentified data, analytic code, and data dictionaries will be made available on the NHLBI BioLINCC data repository (https://biolincc.nhlbi.nih. gov/) upon publication.